MAR-MIDODRINE TABLET

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Kupi sada

Preuzimanje Svojstava lijeka (SPC)
16-06-2020

Aktivni sastojci:

MIDODRINE HYDROCHLORIDE

Dostupno od:

MARCAN PHARMACEUTICALS INC

ATC koda:

C01CA17

INN (International ime):

MIDODRINE

Doziranje:

2.5MG

Farmaceutski oblik:

TABLET

Sastav:

MIDODRINE HYDROCHLORIDE 2.5MG

Administracija rute:

ORAL

Jedinice u paketu:

100

Tip recepta:

Prescription

Područje terapije:

ALPHA-ADRENERGIC AGONISTS

Proizvod sažetak:

Active ingredient group (AIG) number: 0123066001; AHFS:

Status autorizacije:

APPROVED

Datum autorizacije:

2018-03-19

Svojstava lijeka

                                Page 1 of 23
PRODUCT MONOGRAPH
Pr
MAR-MIDODRINE
MIDODRINE HYDROCHLORIDE TABLETS
2.5 MG AND 5 MG
MANUFACTURER’S STANDARD
VASOPRESSOR
Marcan Pharmaceuticals Inc.
Date of Preparation:
2 Gurdwara Road, Suite #112,
June 16, 2020
Ottawa, ON, K2E 1A2
Submission Control No:
239625
Page 2 of 23
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION
.................................................................... 3
SUMMARY PRODUCT INFORMATION
.....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
................................................................................................................
6
DRUG INTERACTIONS
...............................................................................................................
12
DOSAGE AND ADMINISTRATION
...........................................................................................
12
OVERDOSAGE
.............................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................
14
STORAGE AND STABILITY
......................................................................................................
15
PART II: SCIENTIFIC INFORMATION
........................................................................................
12
PHARMACEUTICAL INFORMATION
......................................................................................
12
CLINICAL TRIALS
...................................................................................................................
                                
                                Pročitajte cijeli dokument
                                
                            

Dokumenti na drugim jezicima

Svojstava lijeka Svojstava lijeka francuski 16-06-2020

Upozorenja za pretraživanje vezana za ovaj proizvod

Pogledajte povijest dokumenata